· Original article
Olomorasib trial shows 62% response rate in lung cancer
Olomorasib trial results from Eli Lilly show a 62% tumor response rate in lung cancer, with Phase 3 findings expected in early 2027.
FINANCEVELIX / News
Equities & companies · Page 172
Equities & companies
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
My news topics
My news topics →Choose topics to see up to three latest articles per topic in your account.
Your topic choices are private to your account. No email or push notifications.
Please wait…
Read the original source and publication date in each article.
Results: 3,880 · Page 172 / 324
· Original article
SK hynix dividend: $12 billion payout awaits confirmation
SK hynix dividend plans point to a potential 16 trillion won payout tied to a Kioxia stake sale, with key terms awaiting company confirmation.
· Original article
IBI363 trial results show early lung and gastric cancer signals
Innovent’s IBI363 trial results show early activity in lung and gastric cancers, including a randomized lung cancer benefit, while survival data remain immature.
· Original article
BlueStone earnings: Revenue rises 44%, customers top 1 million
BlueStone earnings for Q2 FY2027 show 44% revenue growth and more than 1 million customers, while gold inflation and product mix shape margins.
· Original article
Lindab earnings: Q3 growth returns, margins trail 2025
Lindab earnings show 2% organic growth in Q3 2026 and a sequential margin recovery, while weak Western European markets weigh on profit and cash flow.
· Original article
Stocks to watch October 26: KEC orders and pharma inspections
Stocks to watch for October 26, 2026 include KEC's ₹2,872 crore orders, FDA observations at Lupin and Gland Pharma, and Raymond's proposed name change.
· Original article
DiDi relisting push draws near-unanimous survey support
A DiDi relisting survey shows strong support for a Hong Kong listing and governance changes, but the voluntary poll is not a formal shareholder vote.
· Original article
Indian stocks: Infosys outlook and bank earnings in focus
Indian stocks face an earnings-heavy October 26 as Infosys cuts its growth outlook, banks report higher profits and YES Bank reviews AT1 coupon options.
· Original article
Divarasib results show 5.7-month survival gain in lung cancer
Divarasib results showed longer survival than two existing lung cancer treatments in Roche’s phase III trial, while regulatory approval remains pending.
· Original article
Apple India software revenue reaches ₹650 crore in FY26
Apple India software revenue reached ₹650 crore in FY26 as Apple Operations India expanded engineering and support services for global group companies.
· Original article
Zentalis trial results show survival gap by Cyclin E1 status
Zentalis trial results show longer survival in Cyclin E1-positive ovarian cancer patients, while safety findings and interim data limit conclusions.
· Original article
Nifty Samvat decline reaches 13% as volatility rises
The Nifty Samvat decline stood near 13% on October 25, 2026, as elevated volatility and broader stock weakness clouded the approach to Samvat 2083.
Charts and market data by TradingView. Availability and delays vary by exchange.